On August 28, 2025, Clearside Biomedical, Inc. was notified by Nasdaq that it did not meet the minimum market value of $50 million required for its continued listing, but has until February 24, 2026, to regain compliance. The company also held a shareholder meeting on August 29, 2025, where a reverse stock split proposal was approved with 46.5 million votes in favor.